Australia · Delayed Price · Currency is AUD Alterity Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
ATH434 demonstrated up to 48% slowing of MSA progression in phase II with a strong safety profile, supported by robust biomarker and imaging data. The upcoming phase III trial will use a 50 mg dose, rigorous patient selection, and validated endpoints, with regulatory alignment and key catalysts expected in 2026.
-
ATH434 demonstrated robust efficacy in phase II for MSA, showing significant slowing of disease progression and strong safety. Commercial potential is high, with peak sales estimated at $2.4 billion and broad neurologist support. Phase III is planned globally, with key milestones expected this year.
Fiscal Year 2025
-
Phase II results showed ATH-434 significantly slowed MSA progression with strong safety and robust commercial potential. FDA meetings are planned for early next year, with phase III preparations underway and IP protections being strengthened.
-
A major biotech showcase drew hundreds of investors and industry leaders, spotlighting advances in cell therapies and neurodegenerative disease treatments. Key presentations included positive Phase II results for an oral therapy for multiple system atrophy, with plans for Phase III and recent capital raised.
-
Phase II results showed ATH434 significantly slowed MSA progression, improved multiple clinical and biomarker endpoints, and was well tolerated. Clinicians highlighted the potential for early intervention to alter disease course, with regulatory engagement and further analyses planned.
Fiscal Year 2024
-
ATH434 showed promising interim results in advanced MSA patients, with 43% improving in daily living activities and supportive biomarker data. The drug was well tolerated, and early-stage patients responded best, guiding future trial design.